At the crossroads of cancer stem cells and targeted therapy resistance
Author:
Funder
National Natural Science Foundation of China
Leading Talent Project of Shanghai
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference141 articles.
1. Targeting cancer with kinase inhibitors;Gross;J. Clin. Investig.,2015
2. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer;Fukuoka;J. Clin. Oncol.,2003
3. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N. Engl. J. Med.,2007
4. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma;Abou-Alfa;J. Clin. Oncol.,2006
5. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers;Diaz;Nature,2012
Cited by 26 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Competing endogenous RNAs regulatory crosstalk networks: The messages from the RNA world to signaling pathways directing cancer stem cell development;Heliyon;2024-08
2. Cancer stem cells: advances in knowledge and implications for cancer therapy;Signal Transduction and Targeted Therapy;2024-07-05
3. SOS1 inhibition enhances the efficacy of and delays resistance to G12C inhibitors in lung adenocarcinoma;2023-12-11
4. SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status;Proceedings of the National Academy of Sciences;2023-11-16
5. Ribosomal S6 protein kinase 4 promotes resistance to EZH2 inhibitors in glioblastoma;Cancer Gene Therapy;2023-09-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3